Kevin Bruce Johnson's Disposal of Tourmaline Bio, Inc. Shares and Stock Options

On October 28, 2025, Kevin Bruce Johnson, the Chief Regulatory Officer of Tourmaline Bio, Inc., disposed of a significant number of shares and stock options in the company. This action was part of a merger agreement between Tourmaline Bio, Inc., Novartis AG, and Torino Merger Sub Inc. The merger involved a cash tender offer where each share of common stock was exchanged for $48.00 in cash. Johnson disposed of 40,538 shares of common stock, leaving him with 11,046 shares, which he subsequently disposed of entirely. Additionally, he disposed of three sets of employee stock options, totaling 200,920 options, which were converted into cash based on the merger agreement terms. This filing highlights the significant changes in ownership and financial obligations triggered by the merger.